This biotech company was involved in HIV solutions...just took one lawsuit...BD
Faced with a patent fight that has frustrated efforts to find a buyer, Trimeris has begun to hand back out $80 million in cash as it winds down its operations. The Trimeris board has authorized returning $50 million to shareholders by the end of the year, and analysts note that all but 10 workers have been let go. Once brimming with potential, Triangle has put its lab up for lease and spun out its R&D work.
Going, going… Trimeris winds down ops - FierceBiotech
0 comments :
Post a Comment